The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
Received 17 September 2019
Accepted for publication 5 December 2019
Published 17 January 2020 Volume 2020:13 Pages 13—27
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Martin Bluth
Dimitrije Pavlovic, 1 Ivana Budic, 2, 3 Tatjana Jevtovic Stoimenov, 4 Dragana Stokanovic, 5 Vesna Marjanovic, 2, 3 Marija Stevic, 6, 7 Milan Slavkovic, 8 Dusica Simic 6, 7
1Clinic for Plastic and Reconstructive Surgery, Clinical Centre Nis, Nis, Serbia; 2Department of Surgery and Anesthesiology, Faculty of Medicine, University of Nis, Nis, Serbia; 3Clinic for Anesthesia and Intensive Therapy, Clinical Centre Nis, Nis, Serbia; 4Institute of Biochemistry, Faculty of Medicine, University of Nis, Nis, Serbia; 5Department of Pharmacology and Toxicology, Faculty of Medicine, University of Nis, Nis, Serbia; 6Department of Surgery and Anesthesiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 7Department of Anesthesiology and Intensive Therapy, University Children’s Hospital, Belgrade, Serbia; 8Department of Pediatric Surgery, University Children’s Hospital, Belgrade, Serbia
Correspondence: Ivana Budic
Department of Surgery and Anesthesiology, Faculty of Medicine, Zorana Djindjica Blvd. 48, Nis 18000, Serbia
Tel +381 63 477380
Fax +381 18 4530514
Email [email protected]
Purpose: This study was conducted to determine the effect of UGT1A9 98T>C, CYP2B6 516G>T and CYP2C9 430C>T genetic polymorphisms on the pharmacokinetics of propofol in children of different sexes and ages who undergone total intravenous anesthesia (ТIVA) and deep sedation during diagnostic and therapeutic procedures.
Patients and Methods: The prospective study included 94 children, ASA I-II status, 1 to 17 years of age, who undergone standard anesthetic protocol for TIVA, which implied the continuous use of propofol. Before the administration of propofol, venous blood was sampled to determine the presence of genetic variations in UGT1A9, CYP2B6 and CYP2C9 gene using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). From each patient included in the study blood samples were taken: 10 mins after the induction of anesthesia, immediately before the discontinuation of the propofol infusion, 10 mins after discontinuation of the propofol infusion and 20 mins after discontinuation of the propofol infusion to determine the pharmacokinetics of the drug in the plasma of the subjects The plasma propofol concentration was determined by HPLC analytical technique.
Results: UGT1A9 genotype is an independent predictor of the propofol concentration in children immediately after the end of the continuous infusion and 10 mins afterwards. In the carriers of the polymorphic UGT1A9 C allele, the propofol distribution constant was higher. The carriers of the polymorphic CYP2B6 T allele received a significantly lower overall and initial dose of propofol. Unlike polymorphism of the UGT1A9 gene, the tested CYP2C9 and CYP2B6 gene polymorphisms are not independent predictors of the pharmacokinetics of propofol.
Conclusion: Further investigations of UGT1A9, CYP2B6 and CYP2C9 and other genes that participate in propofol metabolism as well as detailed analyses of the general conditions, administered therapies and associated diseases could explain the large interindividual variability of propofol metabolism in children.
Keywords: polymorphism, gene, propofol, metabolism, children
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]